Gastrointestinal issues are a common adverse event in clinical trials leading to discontinuation. But really, a lot of other medical conditions can pop up that can disqualify a patient. For example a patient may develop cancer, severe kidney disease, liver disease, etc. I expect the most common adverse event in BETonMACE to be due to concerns of liver damage due to elevated transaminase levels. This is a known issue with apabetalone. We likely won't hear about this stuff until full data release.

BearDownAZ